1. The evidence: key facts & figures good reasons to invest in Belgium

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "1. The evidence: key facts & figures. 2. 7 good reasons to invest in Belgium"

Transcription

1

2 Executive summary 1. The evidence: key facts & figures 2. 7 good reasons to invest in Belgium 3. The Future

3 International recognition of Belgian Biopharma «On four indicators for innovation and industrial development, Belgium is by far the best performing country» (OECD Study 2006) «Belgium in Top 10 of the most innovative pharma valleys worldwide» (Nature, 2010)

4 Belgium the place to be for biopharmaceutical R&D and manufacturing The evidence

5 Belgium, a key player in Europe for biopharma Belgian share in total EU 14% 12% 12% 10% 8% 8% 6% 4% 2% 2% 3% 4% 0% Population GDP Value added R&D-expenditures Export Pharmaceutical industry Source: EFPIA, Eurostat (2012)

6 The biopharmaceutical industry, a growing sector in Belgium Direct employment in the biopharmaceutical industry % , % 24, % 6% 5% 4% 3% % % % Employment in the biopharmaceutical industry Share of manufacturing total Source: National Social Security Office - decentralised statistics (number of jobs on 30th June)

7 The Belgian pharmaceutical industry is highly R&D-intensive 30% R&D intensity (=R&D/production) Pharmaceutical industry 25% 20% 15% 10% 5% 0% Source: EFPIA (average R&D-intensity ) ; * EU28, Switzerland, Norway Pharmaceutical R&D-centers located in Belgium account for one fifth of the total R&D-expenditures made by those companies worldwide

8 The weight of the pharmaceutical R&D nearly doubled in ten years R&D-expenditures in pharmaceutical products in million Share (%) 30% 16% % 30% 25% 20% 15% 10% 5% 0% intra-muros R&D share in total intra-muros R&D in private sector Source: Belspo * intra-muros R&D (based on product groups classification)

9 The positive trade balance contributes increasingly to the standard of living in Belgium 20,0 In billion Trade balance 16,0 12,0 8, ,0 0, All products Belgium Pharmaceuticals Source: NBB according to harmonised system Transit activities and distribution centres included Pharmaceuticals: chapter 30

10 The largest number of medicines in development in the world per capita Number of medicines under development per million inhabitants ,2 14,2 11,7 10,5 7,0 7,0 5 0 B UK NL US F D Number of medicines under development Source: Adis, CIA

11 Belgium, a European leader in the number of clinical trials in phase 1 & 2 per capita 2012, # trials starting per million inhabitants Phase 1 Phase 2 x # of trials started Belgium Denmark Switzerland Austria Sweden Netherlands Norway Spain France Finland United Kingdom Germany Italy SOURCE: ClinicalTrial.gov; Worldbank 11

12 Delivery of Belgian Biopharma A world center of vaccines research & development and manufacturing Major breakthroughs : 5 of the 100 essential medicines according to the World Health Organisation have been developed in Belgian laboratories, specifically those used to treat mental illness, colon cancer, fungal and worm infections Other breakthroughs in the field of HIV/Aids, tuberculosis, malaria, epilepsy, immunotherapy...

13 Why is Belgium so attractive for biopharma? The reasons

14 7 reasons to invest in Belgium 1. A prominent location 2. A unique academic and industrial network 3. A highly qualified and productive workforce 4. A supportive regulatory environment 5. A very favorable public opinion 6. A competitive tax environment 7. The quality of life

15 A prominent location, an excellent logistical and business infrastructure A strategic and central position at the political heart of Europe (many international organizations and major corporate headquarters) Access to a potential market of 500 million people A first-class logistical and business infrastructure (excellent transport facilities and top-rate telecommunications network)

16 The Belgian logistics platform offers a competitive differentiator for the chemical industry Considering costs, transport system, accessibility, supply, labour and know-how Best locations for logistics in Europe Regions* Ranking* Liège (Belgium) 1 Limburg (Belgium) 2 Hainaut (Belgium) 3 Nord-Pas-de Calais (France) 4 Namur (Belgium) 5 Luxembourg (Belgium) 6 Alsace (France) 7 Oost-Vlaanderen (Belgium) 8 Antwerp (Belgium) 9 Arnsberg (Germany) 10 Source: European Distribution Report, Cushman & Wakefield, 2010 * NUTS-2 definition

17 Pharmaceuticals & air cargo : figures Belgian trade of pharmaceuticals by air freight (2013) in tons Asia Pacific* North America Africa Latin America Europe Export Import Source: Brussels Airport *including Middle-East & South Asia

18 Belgium: a unique academic & industrial network 12 universities among 2 in the World Top 100 of Universities in Life Sciences (Academic Ranking of World Universities 2013) High concentration of university hospitals A broad offering of science parks with incubation and innovation centers Highly specialised research institutes with international reputation (e.g. VIB)

19 Belgium: a highly qualified & productive workforce One of the highest productivity rates in the world («The Conference Board» 2010) A highly skilled workforce

20 Belgium: a supportive regulatory environment The fastest approval for phase 1 clinical trials in Europe (2 weeks) Full support of public authorities for the development of biotech clusters (VIB, WelBio, Biowin, FlandersBio, BrusselsLifeTech) Active and supporting industry associations with excellent contacts with the authorities Pharma.be for market access and regulatory affairs Bio.be Biowin, FlandersBio and BrusselsLifeTech for biotech and SMEs

21 Belgium: a very favorable public opinion The highest appreciation of the biopharmaceutical industry in the world 90 % of positive replies Pharmaceutical industry public s image BEL DEU FRA GBR ITA NL ESP SWE POL CZE HUN pharmaceutical industry 2000 pharmaceutical industry 2010 Source: CEFIC PES 2010

22 Belgium: a competitive tax environment Tax-free return on qualifying equity Notional Interest deduction Special tax regime for expatriates Withholding tax exemptions Belgian tax incentives No capital duty Tax rulings with emphasis for multinationals R&D tax incentives VAT grouping 80% patent income reduction (maximum tax is 6.8%, lowest in the EU) 80% exemption payroll withholding tax for scientific researchers Refundable R&D tax credit system Increased investment deduction and flexible depreciation rules for R&D

23 Belgium: a competitive tax environment Unique notional interest deduction for Belgian companies and branches on their (adjusted) equity What is it? A notional interest calculated on the equity and deducted yearly from the taxable basis Used to off-set operational or financial income (lower effective tax rate) Automatically applicable to all Belgian companies and branches of foreign companies For SME s : the deduction rate for income 2012 is increased by 0.5% to 3.5%

24 Belgium: a competitive tax environment The lowest effective European tax rate on revenues from patent income What is it? Deduction of 80% of the income from patents from the taxable basis, resulting in an effective tax rate of maximum 6.8% on this income

25 Belgium: a competitive tax environment Patents concerned : self-developed by a Belgian company or branch in R&D centers (*) in Belgium or abroad acquired by a Belgian company or branch provided they are being further developed in R&D centers (*) in Belgium or abroad licensed to the Belgian company or branch provided they further develop in R&D centers (*) in Belgium or abroad. (*) R&D center must qualify as branch of activity.

26 Belgium: a competitive tax environment 80% exemption from withholding tax in favour of employers who employ researchers (PhD, engineers, master degrees and master-equivalent) Principle : the salary withholding tax is normally retained on the remunerations paid to the researcher, but the amount of tax so retained must not be totally paid to the tax administration The company benefits from a substantial reduction on the cost of employment of researchers.

27 Belgium: The quality of life A very attractive country to live in. A few assets : The lowest real estate costs in Europe One of the best healthcare systems in the world A developed transport network A multicultural and multilingual environment Brussels, the greenest capital in Europe Many high-level international schools..

28 Belgium the place to be for biopharmaceutical R&D and manufacturing The Future

29 Investments MSD Heist-op-den-Berg Multiyear investment program UCB - Braine-L Alleud Biotechnology pilot plant Janssen Pharmaceutica - Geel Chemical Development Pilot Plant

30 Investments GSK Vaccines Wavre Building for the production of clinical lots and start of expansion projects Pa and IPV Baxter Bioscience Lessines Installation and qualification of an aseptic filling line under isolator

31 Investments MaSTherCell Gosselies Building of clean rooms for the production of ATMP Alcon Puurs Expansion of production lines

32 Examples of innovative products in Belgium Ablynx: a pioneer in next generation biologics ActoGeniX: new generation of biological drugs Baxter: medical devices, pharmaceuticals and biotechnology, including specialty biologics Cardio3 BioSciences: regenerative and protective therapies for cardiovascular diseases DelphiGenetics : develops innovative products and services in DNA engineering. Eurogentec: worldwide supplier of products and services to Life-Science, Diagnostics and Pharmaceutical community Galapagos: new mode of action drugs Genzyme: A world leader in treatments of rare genetic diseases GSK Biologicals: Innovative Adjuvant Systems: Enhance immune response to the prophylactic vaccines / Open way for new types of vaccines (therapeutic)

33 Examples of innovative products in Belgium Janssen pharmaceutica: A world leader in psychiatry, neurology and infectious diseases MSD Belgium : innovative medicines, vaccines, biologic therapies and animal health products to help improve health and well-being Pfizer: producing medicines for human health covering many different therapeutic areas remynd: developing disease-modifying treatments against Alzheimer s, Parkinson s, Diabetes and other protein misfolding disorders ThromboGenics: a specialty bio-pharmaceutical company with a focus on retinal disorders, novel vascular and cancer treatments TiGenix: innovative local treatments for damaged and osteoarthritic joints THT (Prayon Group): the science of lactic ferments UCB: Combining biology and chemistry to make major breakthroughs against severe diseases

34 More than 200 life sciences companies invest in Belgium Shouldn t you?

35 Find more about Companies Belgian network (links) News Agenda

36 essenscia Belgian Federation for Chemistry and Life Sciences Industries Contact: Yves Verschueren, Managing Director essenscia T Corine Petry, Head of Communication essenscia T

Join our scientific talent community

Join our scientific talent community Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into

More information

UNIQUE TAX INCENTIVES in BELGIUM

UNIQUE TAX INCENTIVES in BELGIUM Federal Public Service Finance UNIQUE TAX INCENTIVES in BELGIUM 2014 Fiscal Department for Foreign Investments 25 22,3 23 24,2 26,3 25,1 28,2 31 31,3 34 34,3 37,1 37,9 36,5 38,6 40,1 2 Effective (Average)

More information

Increasing Innovation in R&D - Seizing early stage external growth opportunities

Increasing Innovation in R&D - Seizing early stage external growth opportunities Increasing Innovation in R&D - Seizing early stage external growth opportunities Paul R. Eynott, PhD sanofi-aventis, US paul.eynott@sanofi-aventis.com -1- Sommaire -2- CHRISTOPHER A. VIEHBACHER Chief Executive

More information

Cross-country comparison of health care system efficiency

Cross-country comparison of health care system efficiency Cross-country comparison of health care system efficiency Isabelle Joumard, OECD, Economics Department IMF conference, June 21, 2011 Public Health Care Reforms: Challenges and Lessons for Advanced and

More information

Europe attractiveness in International Clinical Research. Survey 2012 Support for December 17th meeting

Europe attractiveness in International Clinical Research. Survey 2012 Support for December 17th meeting Europe attractiveness in International Clinical Research Survey 2012 Support for December 17th meeting 5/8/2014 Table of contents 1. OBJECTIVES, GUIDING PRINCIPLES AND METHODOLOGY 2. RESULTS FOR PHASES

More information

The pharmaceutical sector in Belgium :

The pharmaceutical sector in Belgium : PhaRma FIGURES 2015 The pharmaceutical sector in Belgium : A cornerstone of the Belgian economy, a laboratory of hope for patients The core figures of 2015 confirm the strength of the pharmaceutical sector

More information

THE BELGIAN PHARMACEUTICAL CLUSTER

THE BELGIAN PHARMACEUTICAL CLUSTER THE BELGIAN PHARMACEUTICAL CLUSTER Table of Contents 1.0 Executive Summary... 1 2.0 Overview of Belgium... 2 2.1 Regional Overview... 2 2.2 Belgian Economic Performance... 3 2.3 Competitive Analysis...

More information

Legislative Council Secretariat FACT SHEET. Pharmaceutical industry in Denmark

Legislative Council Secretariat FACT SHEET. Pharmaceutical industry in Denmark FACT SHEET Pharmaceutical industry in Denmark 1. Introduction 1.1 The Danish pharmaceutical industry is known worldwide for providing quality drugs and medical products. In 2012, Denmark was the 16 th

More information

The Special Non-resident Tax Regime for Expatriate Employees in Belgium

The Special Non-resident Tax Regime for Expatriate Employees in Belgium H UMAN C APITAL t The Special Non-resident Tax Regime for Expatriate Employees in Belgium Contents 1. Qualifying Conditions 2. The special tax regime a. Generalities b. Non-taxable allowances c. Calculation

More information

Health Care Systems: An International Comparison. Strategic Policy and Research Intergovernmental Affairs May 2001

Health Care Systems: An International Comparison. Strategic Policy and Research Intergovernmental Affairs May 2001 Health Care Systems: An International Comparison Strategic Policy and Research Intergovernmental Affairs May 21 1 Most industrialized countries have established hybrid systems in which the public sector,

More information

TAX INCENTIVES FOR R&D ACTIVITIES

TAX INCENTIVES FOR R&D ACTIVITIES STRENGTH THROUGH UNITY Federal Public Service FINANCE TAX INCENTIVES FOR R&D ACTIVITIES Tax year 2016 - Income year 2015 10 reasons to invest in R & D in Belgium 1. Patent income deduction A deduction

More information

THE ORGANISATION AND FINANCING OF HEALTH CARE SYSTEM IN LATVIA

THE ORGANISATION AND FINANCING OF HEALTH CARE SYSTEM IN LATVIA THE ORGANISATION AND FINANCING OF HEALTH CARE SYSTEM IN LATVIA Eriks Mikitis Ministry of Health of the Republic of Latvia Department of Health Care Director General facts, financial resources Ministry

More information

Setting up your Business in Turkey Issues to consider

Setting up your Business in Turkey Issues to consider Turkey is located as a bridge between two continents and in close proximity to Europe, the Middle East and the Caucasus. The proximity to the Balkans and the rest of Europe as well as to the growing emerging

More information

ENVIRONMENTAL EXPENSES AND INNOVATIONS IN CONTRAST WITH ECONOMIC DEVELOPMENT

ENVIRONMENTAL EXPENSES AND INNOVATIONS IN CONTRAST WITH ECONOMIC DEVELOPMENT Institute of Agricultural and Food Economics National Research Institute, Warsaw, Poland ENVIRONMENTAL EXPENSES AND INNOVATIONS IN CONTRAST WITH ECONOMIC DEVELOPMENT Szczepan Figiel INTERNATIONAL CONFERENCE

More information

MENTAL HEALTH AND WORK Policy challenges and policy developments in OECD countries

MENTAL HEALTH AND WORK Policy challenges and policy developments in OECD countries MENTAL HEALTH AND WORK Policy challenges and policy developments in OECD countries Shruti Singh, Labour Market Economist Directorate for Employment, Labour and Social Affairs Global Healthy Workplace Awards

More information

Benefits of using HK company for entering into China consumer market

Benefits of using HK company for entering into China consumer market Intertrust Alex Cho November 2006 1 Benefits of using HK company for entering into China consumer market Alex Cho 28 November 2006 Intertrust Alex Cho November 2006 2 China Consumer Market restrictions

More information

Facts&figures of pharmaceutical industry in Italy. June 2016

Facts&figures of pharmaceutical industry in Italy. June 2016 Facts&figures of pharmaceutical industry in Italy June 2016 Key figures of pharma sector in Italy (% on total), member of Farmindustria, representing 90% of industrial value of pharmaceutical sector in

More information

10 reasons to invest in France August 2011 IFA

10 reasons to invest in France August 2011 IFA 10 reasons to invest in France August 2011 IFA 1 France: A global economic power The 2 nd largest economic power in the European Union. Source: IMF, 2011 The world s 6 th largest exporter of goods and

More information

Economic Analysis of the Warehousing & Distribution Market in Northwest Europe

Economic Analysis of the Warehousing & Distribution Market in Northwest Europe Economic Analysis of the Warehousing & Distribution Market in Northwest Europe Indra Vonck, M.sc. ITMMA University of Antwerp Prof. Dr. Theo Notteboom ITMMA University of Antwerp Press meeting, Brussels,

More information

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Tariq Sadat PhD Candidate School of Economics, Finance and Marketing, RMIT University, Australia Roslyn

More information

EFPIA Position Paper on REACH. Executive Summary. Position Paper. Draft Final. Author: EFPIA Date: October 2015 Version: Final

EFPIA Position Paper on REACH. Executive Summary. Position Paper. Draft Final. Author: EFPIA Date: October 2015 Version: Final Draft Final EFPIA Position Paper on REACH Author: EFPIA Date: October 2015 Version: Final Position Paper Executive Summary An increasing number of substances used in the pharmaceutical manufacturing process

More information

THE BIOTECH & PHARMACEUTICAL INDUSTRY

THE BIOTECH & PHARMACEUTICAL INDUSTRY THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues

More information

BRAZIL-LATINAM WELCOME OFFICE

BRAZIL-LATINAM WELCOME OFFICE BRAZIL-LATINAM WELCOME OFFICE in Wallonia - Brussels, Europe in your hands! Wallonia Bel g i u m, you r bu si n e s s pa r t n er i n the heart of Eu rop e THE HEART OF EUROPE Wallonia-Brussels, economic

More information

YOUR FUTURE IN EUROPE STARTS IN BELGIUM. 10 good reasons to invest in Belgium

YOUR FUTURE IN EUROPE STARTS IN BELGIUM. 10 good reasons to invest in Belgium YOUR FUTURE IN EUROPE STARTS IN BELGIUM 10 good reasons to invest in Belgium Welcome to Belgium Located in the heart of Western Europe, Belgium enjoys a key position in the European and international economy.

More information

How many students study abroad and where do they go?

How many students study abroad and where do they go? From: Education at a Glance 2012 Highlights Access the complete publication at: http://dx.doi.org/10.1787/eag_highlights-2012-en How many students study abroad and where do they go? Please cite this chapter

More information

EBiSC the first European bank for induced pluripotent stem cells

EBiSC the first European bank for induced pluripotent stem cells Press Release EBiSC the first European bank for induced pluripotent stem cells Pharmaceutical companies who are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA)

More information

PUBLIC VS. PRIVATE HEALTH CARE IN CANADA. Norma Kozhaya, Ph.D Economist, Montreal economic Institute CPBI, Winnipeg June 15, 2007

PUBLIC VS. PRIVATE HEALTH CARE IN CANADA. Norma Kozhaya, Ph.D Economist, Montreal economic Institute CPBI, Winnipeg June 15, 2007 PUBLIC VS. PRIVATE HEALTH CARE IN CANADA Norma Kozhaya, Ph.D Economist, Montreal economic Institute CPBI, Winnipeg June 15, 2007 Possible private contribution Possible private contribution in the health

More information

Belgium Belgique België Belgien Bélgica. Belgium. Brilliant investment, sweet return

Belgium Belgique België Belgien Bélgica. Belgium. Brilliant investment, sweet return Belgium Belgique België Belgien Bélgica Belgium Brilliant investment, sweet return Belgium 2 Brilliant investment, sweet return Content Introduction... 4 Belgium most globalised country in the world for

More information

A survey conducted by: The Swedish Drug Development Pipeline May 2011

A survey conducted by: The Swedish Drug Development Pipeline May 2011 A survey conducted by: The Swedish Drug Development Pipeline May 2011 The survey In February March 2011 a survey of the Swedish Drug Development Pipeline was conducted by SwedenBIO in cooperation with

More information

VULNERABILITY OF SOCIAL INSTITUTIONS

VULNERABILITY OF SOCIAL INSTITUTIONS VULNERABILITY OF SOCIAL INSTITUTIONS 2 December 2014 Paris Seminar in Demographic Economics Falilou FALL Senior Economist OECD Economics Department 1 Introduction and outline Social institutions and the

More information

Expenditure on Health Care in the UK: A Review of the Issues

Expenditure on Health Care in the UK: A Review of the Issues Expenditure on Health Care in the UK: A Review of the Issues Carol Propper Department of Economics and CMPO, University of Bristol NIERC 25 April 2001 1 Expenditure on health care in the UK: The facts

More information

Homeopathic and anthroposophic medicinal products. A thriving European tradition

Homeopathic and anthroposophic medicinal products. A thriving European tradition Homeopathic and anthroposophic medicinal products A thriving European tradition A THRIVING EUROPEAN TRADITION Sales of homeopathic and anthroposophic medicinal products per inhabitant (in relation to GDP

More information

WHY INVEST IN FRANCE?

WHY INVEST IN FRANCE? WHY INVEST IN FRANCE? A COUNTRY AT THE HEART OF THE EU SINGLE MARKET AND A GATEWAY TO THE EMEA 10 KEY INFO IN POINTS 1 A GLOBAL ECONOMIC POWER largest exporter of services. (WTO, 2013) France is the second

More information

Translational research infrastructure in Neurosciences 15.06.2011/Bruxelles

Translational research infrastructure in Neurosciences 15.06.2011/Bruxelles ITMO Neurosciences, sciences cognitives, neurologie, psychiatrie Translational research infrastructure in Neurosciences 15.06.2011/Bruxelles ITMO Technologie pour la santé 1 NEUROSCIENCE MEDICAL CHALLENGES

More information

Competitive Advantages for Pharma Investing in Belgium

Competitive Advantages for Pharma Investing in Belgium Competitive Advantages for Pharma Investing in Belgium Creating Value in the Heart of Europe Thursday 21 November 2013 Location: CIPAL Cipalstraat, 2440 Geel A visit of the Genzyme Geel plant will be organised

More information

IMI2: why, what, how?

IMI2: why, what, how? IMI2: why, what, how? The Right prevention and treatment, to the right patient, at the right time Isabelle Thizon-de Gaulle VP, Strategic initiatives & Scientific relations Sanofi R&D Innovative Medicines

More information

The European. Medical Technology industry

The European. Medical Technology industry The European Medical Technology industry Table of Contents What is Medical Technology? 01 Innovation 07 Employment 11 Companies 15 Expenditure on Medical Technology 17 MedTech Market 21 Trade 29 About

More information

Role of ICTs and knowledge-based industries in industrial restructuring the Finnish experience

Role of ICTs and knowledge-based industries in industrial restructuring the Finnish experience Role of ICTs and knowledge-based industries in industrial restructuring the Finnish experience Antti Eskola Ministry of Trade and Industry Helsinki, Finland UNECE Trade and Industry Development Week 24

More information

Finland must take a leap towards new innovations

Finland must take a leap towards new innovations Finland must take a leap towards new innovations Innovation Policy Guidelines up to 2015 Summary Finland must take a leap towards new innovations Innovation Policy Guidelines up to 2015 Summary 3 Foreword

More information

Figure 1 Statutory corporate income tax rates

Figure 1 Statutory corporate income tax rates Figure 1 Statutory corporate income tax rates 7 6 1982 2001 5 4 3 2 1 Austria Belgium Canada Finland France UK Germany Greece Ireland Italy Japan Netherlands Notes: For countries using different tax rates,

More information

Worldwide Major Vaccine Manufacturers in Figures

Worldwide Major Vaccine Manufacturers in Figures Worldwide Major Vaccine Manufacturers in Figures Edition 2004 Summary The European Vaccine Manufacturers Association has conducted a survey with a view to assessing economic indicators amongst major worldwide

More information

Foreign Direct Investment in the United States. Organization for International Investment

Foreign Direct Investment in the United States. Organization for International Investment Foreign Direct Investment in the United States Organization for International Investment March 18, 2009 Key Findings FOREIGN DIRECT INVESTMENT IN THE UNITED STATES Foreign Direct Investment in the United

More information

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Agenda Section 1 Overview on the Top Ten Pharmaceutical Companies Section

More information

Automating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se

Automating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se Automating Cell Biology Annual general meeting, September 7, 2015 www.phiab.se 1 PHASE HOLOGRAPHIC IMAGING (PHI) Began as a research project at Lund University, Sweden, in 2000 Founded in 2004 Sales in

More information

MALAYSIA: THE EMERGING EDUCATION HUB

MALAYSIA: THE EMERGING EDUCATION HUB MALAYSIA: THE EMERGING EDUCATION HUB Malaysia aspires to be a regional education hub by 2020 Since 2002, the Ministry of Higher Education has vigorously embarked on initiatives to elevate standards of

More information

THE ISRAELI TAX SYSTEM. Iris Stark, CPA

THE ISRAELI TAX SYSTEM. Iris Stark, CPA THE ISRAELI TAX SYSTEM Iris Stark, CPA October 2012 THE ISRAELI TAX SYSTEM Taxation in Israel is based on an individual method. Accordingly, as of 2003, all Israeli residents are liable for payment of

More information

POLAND Modern and Strong Economy

POLAND Modern and Strong Economy POLAND Modern and Strong Economy Business opportunities for Korean companies in Poland Consulate General of the Republic of Poland in Istanbul Mr Grzegorz Rybarski 1st Counsellor/Consul Filip Hewelke Embassy

More information

PUBLIC & PRIVATE HEALTH CARE IN CANADA

PUBLIC & PRIVATE HEALTH CARE IN CANADA PUBLIC & PRIVATE HEALTH CARE IN CANADA by Norma Kozhaya, Ph.D. Economist, Montreal Economic Institute before the Canadian Pension & Benefits Institute Winnipeg - June 15, 2007 Possible private contribution

More information

INVEST IN FRANCE - April 2015 ed by: oduc Pr

INVEST IN FRANCE - April 2015 ed by: oduc Pr INVEST IN FRANCE FRANCE MEETS ALL THE REQUIREMENTS FOR THE SUCCESS OF YOUR INVESTMENT A preferred destination for international investors. In 2014, 1,014 investment decisions created or maintained 26,535

More information

Appendix. Appendix Figure 1: Trends in age-standardized cardiometabolic (CVD and diabetes) mortality by country.

Appendix. Appendix Figure 1: Trends in age-standardized cardiometabolic (CVD and diabetes) mortality by country. Appendix Appendix Figure 1: Trends in age-standardized cardiometabolic (CVD and diabetes) mortality by country. Men Age standardized cardiometabolic death rate per 100,000 800 700 600 500 400 300 200 800

More information

Introduction to Sanofi and Genzyme

Introduction to Sanofi and Genzyme Introduction to Sanofi and Genzyme 495/MetroWest Partnership's Conference Panel December 15, 2015 Michelle Multiple Sclerosis Denmark Overview Who is Sanofi? Who is Genzyme MetroWest Investment Talent

More information

ALTER DOMUS. ALTER DOMUS Belgium

ALTER DOMUS. ALTER DOMUS Belgium BELGIUM ALTER DOMUS Alter Domus is a leading provider of Fund and Corporate Services, dedicated to international private equity & infrastructure houses, real estate firms, private debt managers, multinationals,

More information

Operational Companies VAT Indirect Taxes. Why Luxembourg: VAT advantages for commercial companies*

Operational Companies VAT Indirect Taxes. Why Luxembourg: VAT advantages for commercial companies* Operational Companies VAT Indirect Taxes Why : VAT advantages for commercial companies* Why : VAT advantages for commercial companies as an international decision-making, financing or distribution hub:

More information

Overview of the EHR4CR project Electronic Health Record systems for Clinical Research

Overview of the EHR4CR project Electronic Health Record systems for Clinical Research Overview of the EHR4CR project Electronic Health Record systems for Clinical Research Dipak Kalra UCL on behalf of the EHR4CR Consortium ENCePP Plenary Meeting, 3rd May 2012, London The problem (as addressed

More information

Malta Companies in International Tax Structuring February 2015

Malta Companies in International Tax Structuring February 2015 INFORMATION SHEET No. 126 Malta in International Tax Structuring February 2015 Introduction Malta is a reputable EU business and financial centre with an attractive tax regime and sound legislative framework.

More information

Committee on Finance to create sustainable longterm economic growth in Canada

Committee on Finance to create sustainable longterm economic growth in Canada Biotechnology Innovation: A submission to the House of Commons Standing Committee on Finance to create sustainable longterm economic growth in Canada EXECUTIVE SUMMARY: The bio-economy in Canada represents

More information

New York Bio Conference 2016. Mark J. Alles Chief Executive Officer

New York Bio Conference 2016. Mark J. Alles Chief Executive Officer New York Bio Conference 2016 Mark J. Alles Chief Executive Officer Great Progress AGE 72 World Life Expectancy 2005-2014* 17 new drugs for rare diseases 71.5 71 Two new MS drugs First drug to target root

More information

A targeted approach to infectious diseases and microbiology

A targeted approach to infectious diseases and microbiology What is a Technological Research Institute? A Technological Research Institute is an interdisciplinary institute bringing together industry and public research skills through medium-to long-term strategic

More information

SWECARE FOUNDATION. Uniting the Swedish health care sector for increased international competitiveness

SWECARE FOUNDATION. Uniting the Swedish health care sector for increased international competitiveness SWECARE FOUNDATION Uniting the Swedish health care sector for increased international competitiveness SWEDEN IN BRIEF Population: approx. 9 800 000 (2015) GDP/capita: approx. EUR 43 300 (2015) Unemployment

More information

Transfer issues and directions for reform: Australian transfer policy in comparative perspective

Transfer issues and directions for reform: Australian transfer policy in comparative perspective Transfer issues and directions for reform: Australian transfer policy in comparative perspective Peter Whiteford, Social Policy Research Centre, University of New South Wales p.whiteford@unsw.edu.au 1

More information

What if BAU would come true?

What if BAU would come true? What if BAU would come true? Scanning transport CO 2 emissions in the EU Petri Tapio & Jyrki Luukkanen Finland Futures Research Centre The approach Introduction of general trends on EU15 level GDP Transport

More information

Cargo Flows & Hot Spots

Cargo Flows & Hot Spots Cargo Flows & Hot Spots Peter Colon Buck Consultants International German-Dutch Logistics Conference March 2015 Buck Consultants International P.O. Box 1456 6501 BL Nijmegen The Netherlands P: +31 24 379

More information

Australia Life Sciences Market

Australia Life Sciences Market Australia Life Sciences Market Monique Roos, Commercial Specialist U.S. Commercial Service, Sydney, Australia November 2014 Geographical Size Population Density More than 80% of population in this ring

More information

The Texas Biotechnology Industry

The Texas Biotechnology Industry The Texas Biotechnology Industry 2014 Fortune 1000 company NBTY opens state-of-the-art vitamin manufacturing plant in San Antonio See Page 15 Allergan installs new production line at Waco pharmaceutical

More information

ANALYSIS OF THE STAKEHOLDER CONSULTATION ON

ANALYSIS OF THE STAKEHOLDER CONSULTATION ON ANALYSIS OF THE STAKEHOLDER CONSULTATION ON Science and Technology, the key to Europe s future: guidelines for future European policy to support research COM(353)2004 DG Research, European Commission,

More information

Global Market trends and developments. Paul Smit SVP of Strategy & Business Development May 31 st, 2007

Global Market trends and developments. Paul Smit SVP of Strategy & Business Development May 31 st, 2007 Global Market trends and developments Paul Smit SVP of Strategy & Business Development May 31 st, 2007 Agenda Healthcare and Demographics Healthcare System challenges Key Technology Developments Conclusions

More information

September 29, About BIO

September 29, About BIO The Comments of the Biotechnology Industry Organization on the Discussion Paper on Compulsory Licenses Published by the Department of Industrial Policy and Promotion within India's Ministry of Commerce

More information

PHARMACEUTICAL PRICING POLICY PROJECT

PHARMACEUTICAL PRICING POLICY PROJECT PHARMACEUTICAL PRICING POLICY PROJECT Executive Summary and Conclusions Valérie Paris Warsaw 19 March 2008 OECD pharmaceutical pricing policy project 2005-2007 Objective: Assess the cross-national impact

More information

Hong Kong Poised to be the Asia s Biotechnology Hub

Hong Kong Poised to be the Asia s Biotechnology Hub Think Asia, think Hong Kong - London 13-09-2011 www.hkbio.org.hk BioTech at Science Park Your Safe and Fast Track to China Hong Kong Poised to be the Asia s Biotechnology Hub Albert Cheung Hoi Yu, Ph.D.

More information

Santaravalley: Integrating scientific research, high-tech business and academia Prof. Vladas Algirdas Bumelis President of Santara valley Association Vilnius, Lithuania 2013July 18 th Santara Valley Association

More information

Leading causes of death in Israel

Leading causes of death in Israel www.health.gov.il Health Information Division Leading causes of death in Israel 2000-2012 Nehama Goldberger, Myriam Aburbeh, Ziona Haklai September 2015 Health.info@moh.health.gov.il Contents Leading causes

More information

Providing Trusted and Innovative Solutions t o the Life Science Communities

Providing Trusted and Innovative Solutions t o the Life Science Communities Providing Trusted and Innovative Solutions t o the Life Science Communities Eurogentec Eurogentec is a leading supplier of trusted and innovative reagents, kits, specialty products and custom research/development

More information

UNCOVERING OPPORTUNITIES IN THE BIOTECH SECTOR - BRAZIL

UNCOVERING OPPORTUNITIES IN THE BIOTECH SECTOR - BRAZIL UNCOVERING OPPORTUNITIES IN THE BIOTECH SECTOR - BRAZIL INTRODUCTION BY INNOVATION CENTRE DENMARK IN SAO PAULO BRAZILIAN BIOTECHNOLOGY SECTOR The Ministry of Science, Technology and Innovation (MCTI) considers

More information

ANTICIPATING POPULATION AGEING CHALLENGES AND RESPONSES. Peter Whiteford Social Policy Division, OECD www.oecd.org www.oecd.

ANTICIPATING POPULATION AGEING CHALLENGES AND RESPONSES. Peter Whiteford Social Policy Division, OECD www.oecd.org www.oecd. ANTICIPATING POPULATION AGEING CHALLENGES AND RESPONSES Peter Whiteford Social Policy Division, OECD www.oecd.org www.oecd.org/els Outline z z z What is the OECD and what does it do? Anticipating the challenges

More information

CEE Insurance the story of uneven recovery

CEE Insurance the story of uneven recovery CEE Insurance the story of uneven recovery May 2014 Andreea Moraru, Senior Banker, EBRD Table of content 1. EBRD Mission and Operations 2. Insurance and Financial Services at EBRD 3. Prospects and Challenges

More information

Value added tax on financial services 1

Value added tax on financial services 1 Value added tax on financial services 1 1. Background Financial services are exempted from value added tax. Proposition No. 1 (2012 2013) to the Storting; Bill and Draft Resolution on Taxes, discussed

More information

MALAYSIA: INVESTMENT IN THE SERVICES SECTOR EDUCATION AND INDUSTRIAL TRAINING

MALAYSIA: INVESTMENT IN THE SERVICES SECTOR EDUCATION AND INDUSTRIAL TRAINING MALAYSIA: INVESTMENT IN THE SERVICES SECTOR EDUCATION AND INDUSTRIAL TRAINING Introduction This booklet is one of a series of 21 booklets prepared by MIDA for the purpose of providing investors with relevant

More information

Developing a local innovation system: the challenge of Trentino

Developing a local innovation system: the challenge of Trentino Developing a local innovation system: the challenge of Trentino Alessandra Proto OECD LEED Trento Centre for Local Development Trento, 28 March 2012 1 THE TRENTINO PROVINCE 520 000 inhabitants in 223 municipalities

More information

The European regulatory system for medicines and the European Medicines Agency

The European regulatory system for medicines and the European Medicines Agency The European regulatory system for medicines and the European Medicines Agency A consistent approach to medicines regulation across the European Union An agency of the European Union This booklet is intended

More information

The Top 200 Point-Of-Care Diagnostics Companies Worldwide

The Top 200 Point-Of-Care Diagnostics Companies Worldwide Brochure More information from http://www.researchandmarkets.com/reports/3616733/ The Top 200 Point-Of-Care Diagnostics Companies Worldwide Description: Did you know? - EKF Diagnostics Holdings plc sold

More information

Government at a Glance 2015

Government at a Glance 2015 Government at a Glance 2015 Size of public procurement Strategic public procurement E-procurement Central purchasing bodies 135 Size of public procurement Public procurement refers to the purchase by governments

More information

Earnings related schemes: Design, options and experience. Edward Whitehouse

Earnings related schemes: Design, options and experience. Edward Whitehouse Earnings related schemes: Design, options and experience Edward Whitehouse World Bank core course Washington DC, March 2014 Objectives Primary objective: ensuring older people have a decent standard of

More information

The Community Innovation Survey 2010 (CIS 2010)

The Community Innovation Survey 2010 (CIS 2010) The Community Innovation Survey 2010 (CIS 2010) THE HARMONISED SURVEY QUESTIONNAIRE The Community Innovation Survey 2010 FINAL VERSION July 9, 2010 This survey collects information on your enterprise s

More information

Transatlantic Trade and Investment Partnership (TTIP): Towards better health outcomes for patients and economic growth

Transatlantic Trade and Investment Partnership (TTIP): Towards better health outcomes for patients and economic growth Transatlantic Trade and Investment Partnership (TTIP): Towards better health outcomes for patients and economic growth 1 About EFPIA Þ EFPIA is the voice of the European innovative pharmaceutical industry,

More information

Private Health insurance in the OECD

Private Health insurance in the OECD Private Health insurance in the OECD Benefits and costs for individuals and health systems Francesca Colombo, OECD AES, Madrid, 26-28 May 2004 http://www.oecd.org/health 1 Outline Q Background, method

More information

Regulatory aspects of Energy Investment Conditions in European Countries

Regulatory aspects of Energy Investment Conditions in European Countries CEER Memo on Regulatory aspects of Energy Investment Conditions in European Countries Ref: C14-IRB-23-03a 27-April-2015 Council of European Energy Regulators asbl Cours Saint-Michel 30a, Box F 1040 Brussels,

More information

INTRODUCTION TO THE TAXATION SYSTEM IN ISRAEL

INTRODUCTION TO THE TAXATION SYSTEM IN ISRAEL INTRODUCTION TO THE TAXATION SYSTEM IN ISRAEL 1. INTRODUCTION The Israeli tax system is based on UK tax principles with substantial modification. On January 1, 2003, Israel introduced a substantial tax

More information

BIOMEDICAL SCIENCES INDUSTRY IN SINGAPORE ROLE OF EDB

BIOMEDICAL SCIENCES INDUSTRY IN SINGAPORE ROLE OF EDB BIOMEDICAL SCIENCES INDUSTRY IN SINGAPORE ROLE OF EDB JAN 2014 1 Singapore s Economic Journey GDP (US$B) 260 240 220 200 180 160 140 120 100 80 60 40 20 0 1960-1969 Labour Intensive 1970 1979 Skill Intensive

More information

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies Greetings from Chicago! Beaches Yes! Pharma Beginnings! Bogota 1974 Selling Drugs in Colombia Global

More information

The European Medical Technology industry IN FIGURES

The European Medical Technology industry IN FIGURES The European Medical Technology industry IN FIGURES Table of contents Foreword 4 What is Medical Technology? 6 Innovation 12 Employment 16 Companies 20 Expenditure on Medical Technology 22 MedTech Market

More information

GLOBAL EDUCATION PROGRAM

GLOBAL EDUCATION PROGRAM GLOBAL EDUCATION PROGRAM RUSSIAN FEDERATION GOVERNMENT-SPONSORED PROGRAM THAT OFFERS RUSSIAN CITIZENS AN OPPORTUNITY TO STUDY AT LEADING FOREIGN UNIVERSITIES REGULATIONS: ABOUT GEP http://educationglobal.ru/o_programme/

More information

Industry Insight - Indian Biopharma

Industry Insight - Indian Biopharma Brochure More information from http://www.researchandmarkets.com/reports/2043221/ Industry Insight - Indian Biopharma Description: Biopharmaceuticals are complex macromolecules (Large molecules) created

More information

The Burden of Rheumatoid

The Burden of Rheumatoid The Burden of Rheumatoid Arthritis (RA) and Patient Access to Treatment by prof. Bengt Jönsson, DR. Gisela Kobelt and PROF. Josef Smolen summary of key findings Table of contents Introduction Introduction

More information

Private Health insurance in the OECD

Private Health insurance in the OECD Private Health insurance in the OECD Benefits and costs for individuals and health systems Francesca Colombo, OECD AES, Madrid, 26-28 May 2003 http://www.oecd.org/health 1 Outline Background, method Overview

More information

Site Selection for Life Sciences Companies in Europe

Site Selection for Life Sciences Companies in Europe INTERNATIONAL CORPORATE TAX Site Selection for Life Sciences Companies in Europe 2015 In association with Content 05 Key findings 09 Life Sciences Clusters in Europe 19 Business environment and agility

More information

Civil service pension schemes. Options for reform

Civil service pension schemes. Options for reform Civil service pension schemes Options for reform World Bank Core Course on Pensions Washington, DC, March, 2014 Agenda Institutional arrangements for public-sector workers pensions Demographic pressures

More information

2015 FOYA Award for facility integration Multipurpose Biologics and Vaccines Production Facility. IDT Biologika 2015 FOYA Award Facility Integration

2015 FOYA Award for facility integration Multipurpose Biologics and Vaccines Production Facility. IDT Biologika 2015 FOYA Award Facility Integration 2015 FOYA Award for facility integration Multipurpose Biologics and Vaccines Production Facility 1 Agenda ABOUT IDT BIOLOGIKA FACILITY HIGHLIGHTS AND INNOVATIVE FEATURES BUILDING CONCEPT AND PROJECT OVERVIEW

More information

Transport Infographics

Transport Infographics Connect to Compete! Generating growth Transport Infographics Creating jobs Innovating to compete Connecting people Transport Generating growth Transport is the lifeblood of the EU economy There are over

More information

Review of R&D Tax Credit. Invitation for Submissions

Review of R&D Tax Credit. Invitation for Submissions Review of R&D Credit invitation for submissions Review of R&D Credit Invitation for Submissions February 2013 Economic and Fiscal Divisions Department of Finance Government Buildings, Upper Merrion Street,

More information

Greece Country Profile

Greece Country Profile Greece Country Profile EU Tax Centre March 2013 Key factors for efficient cross-border tax planning involving Greece EU Member State Double Tax Treaties With: Albania Estonia Lithuania Serbia Armenia Finland

More information